文献速递青光眼

低浓度贝美前列素0.01%与噻吗洛尔0.1%眼用凝胶对比贝美前列素0.03%与噻吗洛尔0.5%滴眼液治疗开角型青光眼或高眼压症:III期随机研究

Low-concentration bimatoprost 0.01% and timolol 0.1% eye gel versus bimatoprost 0.03% and timolol 0.5% eye drops in open-angle glaucoma or ocular hypertension: a phase III randomised study.
PubMed 文献 · Br J Ophthalmol · 2026-03-20

这项III期国际多中心随机平行组研究者设盲研究比较了无防腐剂贝美前列素0.01%/噻吗洛尔0.1%固定组合眼用凝胶与贝美前列素0.03%/噻吗洛尔0.5%固定组合滴眼液在开角型青光眼或高眼压症患者中的疗效与安全性。主要终点第12周08:00眼压较基线变化:凝胶组-10.96±3.43 mmHg,滴眼液组-11.14±3.56 mmHg,最小二乘均值差-0.04±0.24 mmHg(95%CI -0.51至0.43 mmHg),95%CI上限低于预设非劣效界值+1.5 mmHg,两组安全性相当。

要点

  • 第12周08:00眼压较基线变化凝胶组-10.96±3.43 mmHg,滴眼液组-11.14±3.56 mmHg
  • 最小二乘均值差(凝胶减滴眼液)-0.04±0.24 mmHg,95%CI -0.51至0.43 mmHg,上限低于+1.5 mmHg界值
  • 凝胶组无因治疗相关不良事件退出研究,滴眼液组有8例(2.9%)退出

核心结论

  • 低浓度贝美前列素0.01%/噻吗洛尔0.1%固定组合眼用凝胶可被认为是青光眼和高眼压症治疗管理中安全有效的治疗选择。

研究设计与样本

  • III期、国际、多中心、随机、平行组、研究者设盲研究,纳入一线单药治疗眼压控制不充分需双联治疗的开角型青光眼或高眼压症患者,随机接受贝美前列素0.01%/噻吗洛尔0.1%固定组合眼用凝胶或贝美前列素0.03%/噻吗洛尔0.5%固定组合滴眼液每日一次,治疗12周。

主要发现

  • 第12周08:00眼压较基线变化:凝胶组-10.96±3.43 mmHg,滴眼液组-11.14±3.56 mmHg。
  • 最小二乘均值差(凝胶减滴眼液)-0.04±0.24 mmHg(95%CI -0.51至0.43 mmHg),95%CI上限低于预设界值+1.5 mmHg。
  • 其他所有时间点显示相似的降眼压疗效,两组安全性特征相当。
  • 凝胶组无患者因治疗相关不良事件退出研究,滴眼液组有8例(2.9%)退出。

关键数值与推荐

  • 主要疗效终点为评估眼第12周08:00眼压较基线变化,预设非劣效界值为+1.5 mmHg。
  • 第12周08:00最小二乘均值差(凝胶减滴眼液)95%CI上限低于+1.5 mmHg界值。

临床怎么用

  • 作者认为低浓度贝美前列素0.01%/噻吗洛尔0.1%固定组合眼用凝胶可被认为是青光眼和高眼压症治疗管理中安全有效的治疗选择。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND/AIMS: To compare the efficacy and safety of a new preservative-free bimatoprost 0.01%/timolol 0.1% fixed combination (BTFC) eye gel with those of bimatoprost 0.03%/timolol 0.5% fixed combination ophthalmic solution (BTFC eye drops) in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT). METHODS: In this phase III, international, multi-centre, randomised, parallel group, investigator-masked study, patients receiving a first-line monotherapy, having insufficiently controlled intraocular pressure (IOP) and requiring dual therapy were randomised to receive either BTFC eye gel or BTFC eye drops once daily for 12 weeks. The primary efficacy endpoint was the change in IOP from baseline to week 12 at 08:00 in the assessed eye. Further efficacy and safety endpoints were assessed as secondary outcomes. RESULTS: The mean±SD change in IOP from baseline to week 12 at 08:00 was -10.96±3.43 mmHg for the BTFC eye gel group and -11.14±3.56 mmHg for the BTFC eye drop group. The least-squares mean difference (BTFC eye gel minus BTFC eye drops) was -0.04±0.24 mmHg (95% CI -0.51 to 0.43 mmHg), with the upper bound of the 95% CI lower than the predefined margin of +1.5 mmHg at week 12 at 08:00. Similar IOP-lowering efficacy was demonstrated at all other timepoints. The safety profile was comparable between the treatment groups. No patients in the BTFC eye gel group discontinued the study due to a treatment-related adverse event compared with 8 (2.9%) patients in the BTFC eye drop group. CONCLUSION: Low-concentration BTFC eye gel can be considered as a safe and effective treatment in the therapeutic management of glaucoma and OHT.

来源:Br J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Cordeiro MF, Oddone F, Mermeklieva EA, et al. Low-concentration bimatoprost 0.01% and timolol 0.1% eye gel versus bimatoprost 0.03% and timolol 0.5% eye drops in open-angle glaucoma or ocular hypertension: a phase III randomised study. Br J Ophthalmol. 2026. PMID: 41093358. doi:10.1136/bjo-2025-327555

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。